open access
Hypofractionated accelerated radiotherapy in T1–3 N0 cancer of the larynx: A prospective cohort study with historical controls
open access
Abstract
Aim
The goal of this prospective study was to assess the effectiveness of a hypofractionated accelerated regime in treatment of the larynx cancer.
Background
Multiple radiotherapy delivery regimes are used for treatment of the larynx cancer. Hypofractionated regimes could provide similar results with reduced use of radiotherapy facilities.
Material and methods
223 patients with squamous cell carcinoma of the upper or middle larynx have been treated with 63[[ce:hsp sp="0.25"/]]Gy delivered in 28 fractions of 2.25[[ce:hsp sp="0.25"/]]Gy during 38 days, 5 fractions per week. The study endpoints were overall survival, progression-free survival, early and late treatment toxicity. Standard and accelerated radiotherapy groups from the study published by Hliniak et al.[[ce:cross-ref id="crf0065" refid="bib0275"]]20 served as controls.
Results
Five-year actuarial overall survival was 87.5% in the study group, 84.5% in the control group receiving accelerated radiotherapy (33 fractions of 2.0[[ce:hsp sp="0.25"/]]Gy, 6 fractions per week) and 86.2% in the control group (33 fractions of 2.0[[ce:hsp sp="0.25"/]]Gy, 5 fractions per week). Five-year progression-free survival was 73.6%, 77.2% and 66.2%, respectively. Overall, treatment toxicity and complication rates did not differ between the study group and the control groups.
Conclusions
The hypofractionated accelerated radiotherapy protocol using 5 fractions per week reduced the use of radiotherapy facilities. There was no significant difference in overall survival and progression-free survival between the study and control groups treated with accelerated or standard radiotherapy.
Abstract
Aim
The goal of this prospective study was to assess the effectiveness of a hypofractionated accelerated regime in treatment of the larynx cancer.
Background
Multiple radiotherapy delivery regimes are used for treatment of the larynx cancer. Hypofractionated regimes could provide similar results with reduced use of radiotherapy facilities.
Material and methods
223 patients with squamous cell carcinoma of the upper or middle larynx have been treated with 63[[ce:hsp sp="0.25"/]]Gy delivered in 28 fractions of 2.25[[ce:hsp sp="0.25"/]]Gy during 38 days, 5 fractions per week. The study endpoints were overall survival, progression-free survival, early and late treatment toxicity. Standard and accelerated radiotherapy groups from the study published by Hliniak et al.[[ce:cross-ref id="crf0065" refid="bib0275"]]20 served as controls.
Results
Five-year actuarial overall survival was 87.5% in the study group, 84.5% in the control group receiving accelerated radiotherapy (33 fractions of 2.0[[ce:hsp sp="0.25"/]]Gy, 6 fractions per week) and 86.2% in the control group (33 fractions of 2.0[[ce:hsp sp="0.25"/]]Gy, 5 fractions per week). Five-year progression-free survival was 73.6%, 77.2% and 66.2%, respectively. Overall, treatment toxicity and complication rates did not differ between the study group and the control groups.
Conclusions
The hypofractionated accelerated radiotherapy protocol using 5 fractions per week reduced the use of radiotherapy facilities. There was no significant difference in overall survival and progression-free survival between the study and control groups treated with accelerated or standard radiotherapy.
Keywords
Carcinoma; Squamous cell; Larynx; Radiotherapy; Hypofractionated radiotherapy; Accelerated radiotherapy
About this articleTitle
Hypofractionated accelerated radiotherapy in T1–3 N0 cancer of the larynx: A prospective cohort study with historical controls
Journal
Reports of Practical Oncology and Radiotherapy
Issue
Pages
537-543
Published online
2016-11-01
DOI
10.1016/j.rpor.2016.08.001
Bibliographic record
Rep Pract Oncol Radiother 2016;21(6):537-543.
Keywords
Carcinoma
Squamous cell
Larynx
Radiotherapy
Hypofractionated radiotherapy
Accelerated radiotherapy
Authors
Zbigniew Szutkowski
Andrzej Kawecki
Andrzej Jarząbski
Zofia Laskus
Romuald Krajewski
Wojciech Michalski
Paweł Kukołowicz